

Interview with Mr. Masayuki Haga - a global wheelchair rugby player affiliated with PeptiDream



Mr. Masayuki Haga, a wheelchair rugby player affiliated with PeptiDream Inc.

PeptiDream Inc. (hereinafter referred to as "PeptiDream") is a bio-venture company listed on the Tokyo Stock Exchange Prime Market which aims to create innovative drugs by utilizing macrocyclic peptides. The company moved its head office and research center to King SkyFront in July 2017. We interviewed Mr. Haga, who is affiliated with PeptiDream and plays internationally as a wheelchair rugby player, about his activities at PeptiDream as well as about wheelchair rugby.

About PeptiDream

PeptiDream is engaged in drug discovery and development business and primarily conducts drug discovery and development collaborations with leading pharmaceutical companies. In March 2022, through the acquisition of PDRadiopharma, a wholly owned subsidiary of PeptiDream, we have established a platform of radiopharmaceuticals that enables us to conduct manufacturing and sales in one-stop. The company views athletes who compete globally internationally as being in a comparable situation to PeptiDream, which continues to take on challenges in the global market. Through supporting para-athletes, we hope to instill a spirit of challenge within the company and its employees.
(Comments from PeptiDream IR & Public Affairs team)

Activities of Mr. Haga

I belong to the IR & Public Affairs Department and primarily focus on my athletic activities, such as daily training and participating in competitions. I also engage in social contribution activities, such as speaking at SDGs seminars and organizing wheelchair rugby experience sessions at elementary schools. I also attend lunch parties to socialize with employees. The lunch party aims to foster cross-departmental connections among employees, where we chat about why wheelchair rugby is an attractive sport and share everyday topics such as hobbies. The lunch parties are an opportunity to deepen relationships among employees as well, and I hope they provide a positive stimulus. For me personally, it is a great chance to share with others about wheelchair rugby. From such background, I have had uniforms with messages sent to me from the IR & Public Affairs team when I participated in an international wheelchair rugby tournament. My main activities are wheelchair rugby training and participating in matches. I am grateful to my company for supporting me in facilitating my training and providing other assistance.

About Wheelchair Rugby

It is a diverse sport that includes female players, a wide range of disability levels, and participants ranging in age from 15 to around 60 years old. I hope to convey to many people the attractiveness of wheelchair rugby, where players in wheelchairs can collide violently with each other, fall, and run with all their might. Also, the sound of the wheelchairs colliding during a tackle is thrilling, making it an exciting sport even for first-time spectators. I hope everyone will come and watch a match at the venue and feel the excitement.

Thoughts on PeptiDream

The power of sports lies in its ability to unite everyone, including not only the players and team staff, but also the organizers, volunteers, spectators, and supporters. As an employee of PeptiDream, I hope to contribute to uniting the company together as well. In the future, I hope that all the para-athletes affiliated with PeptiDream will be able to increase opportunities for us to participate in events, lectures, and school visits as representatives of PeptiDream.



Mr. Haga who received an uniform with messages

Jiksak Bioengineering, Inc. signed a joint research agreement with Teijin Pharma Limited.



Jiksak Bioengineering, Inc. (head office: Kawasaki City, Kanagawa Pref; hereinafter referred to as Jiksak) signed a joint research agreement with Teijin Pharma Limited (head office: Chiyoda-ku, Tokyo; hereinafter referred to as Teijin Pharma).

The purpose of this joint research is to identify novel drug target genes for neurological intractable diseases using Jiksak's pre-synaptogenesis-inducing microbeads. This research is expected to play a significant role in the elucidation of pathological conditions and the development of treatments. Jiksak and Teijin Pharma will contribute to the development of new treatments for neurological intractable diseases by utilizing cutting-edge biotechnology.

[Click here for details](#)

Held an event!

Business matching event was held with German companies!



Business matching event with the organizations located at King SkyFront was held coincide to the visit of leading German companies in the healthcare sector such as biotechnology, pharmaceutical and others in July.

Eight German companies and approximately ten organizations located in the King SkyFront participated. This deepened mutual understanding through presentations and panel exhibitions, and actively exchanged their opinions.

After presentations introduced the projects of each organization, there were live demonstrations using actual equipment at the panel exhibitions. The event was a remarkable success throughout.

Joined KING SKYFRONT!

TOAGOSEI CO., LTD. opened Kawasaki Frontience R&D Center to strengthen development capabilities in growth areas.

Our company opened Kawasaki Frontience R&D Center in King SkyFront in August 2024 as a new development base in the metropolitan area. We have established specialized facilities that enable advanced research in growth areas such as biochemicals and electronic materials and promote R&D and early commercialization of medical care, next-generation batteries, semiconductors, electronic materials, and more. The center also takes advantage of its convenient location to promote product development in collaboration with customers in the Tokyo metropolitan area, north of the Kanto region, and overseas. In addition, it serves as a center for collaboration with customers and external research institutes by setting up open laboratories to conduct collaborative research, demo experiment, and a communication area to facilitate technological exchange and information dissemination. The new research center is an environment where everyone can work with excitement everyday with the office in the laboratories and free address, aiming to be a center of open innovation that produces original products.



The center also takes advantage of its convenient location to promote product development in collaboration with customers in the Tokyo metropolitan area, north of the Kanto region, and overseas. In addition, it serves as a center for collaboration with customers and external research institutes by setting up open laboratories to conduct collaborative research, demo experiment, and a communication area to facilitate technological exchange and information dissemination. The new research center is an environment where everyone can work with excitement everyday with the office in the laboratories and free address, aiming to be a center of open innovation that produces original products.

[Click here for details](#)

Contributing to people's beauty and health with new functional ingredients derived from natural resources




Sea Act Co., Ltd. is engaged in the research and development and sales of functional cosmetic and food ingredients through the effective use of natural resources. Based on ideas obtained through past usage and knowledge of plant and marine resources, we develop and sell a new cosmetic ingredient that have affinity for the skin and moisturizing properties, as well as a new ingredient that can improve the luster, moisturization, and combing of hair with properties of hair affinity and moisture retention. In addition, from the microalgae *Aurantiochytrium*, we have discovered a new food ingredient and its functions to deal with the modulation of the body due to aging, and sell that as functional food ingredient. Through these functional ingredients, we provide a variety of beauty and health functions to contribute to the sustainable business success of our clients.

[Click here for details](#)

iCONM Now

Stabilizing immune-regulating proteins with a cloak



H. Cabral et al., J. Am. Chem. Soc., in press <http://doi.org/10.1016/j.ymthe.2024.03.022>

A project group for intractable cancer led by Prof. Horacio Cabral, Graduate School of Engineering, The University of Tokyo (iCONM Visiting Researcher) with iCONM has stabilized a complex of interleukin-15 (IL-15) and its receptor alpha domain (IL-15Ra), which is known to have anti-tumor immune activity, by cloaking it (polymer coating) and demonstrated that it is a potent and safe immunotherapy against colorectal cancer in mice. The paper describing the results has been published on the web in Journal of The American Chemical Society. The instability of protein complexes is an obstacle to drug development, but this research established a structure that wraps the protein complexes and protects them from attack by enzymes and/or the immune system. In addition, by using a pH-responsive linker, we have succeeded in releasing the encapsulated protein complex after it reaches the affected site. Protein complexes generally play a role in regulating various functions in vivo, and are expected to be applied not only to cancer therapy but also to a wide range of therapeutic areas, including autoimmune diseases, including many intractable diseases.

Notice from the secretariat

We have updated the KING SKYFRONT pamphlet!

In September, we updated the pamphlet listing the institutions located at KING SKYFRONT. With the addition of new resident institutions, the total number of listed institutions has now reached sixty-four. You can check it out on the KSF Network managed by Kawasaki Institute of Industrial Promotion (KIIP). Please have a look!

[Click here for details](#)

